Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. The discovery, published Dec. 13 in ...

The treatment, called Pasritamig, teaches the immune system's T cells to target and attack cancer cells in the prostate.

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human Phase I trial using a chimeric antigen receptor (CAR) T cell therapy developed by ...

WASHINGTON (Reuters) - Researchers have found a stem cell, a kind of master cell, that may cause at least some types of prostate cancer. Their findings are only experimental -- the stem cells were ...

A new research paper was published in Volume 17 of Oncotarget on March 17, 2026, titled "CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer." Led ...

There is a challenge related to prostate and many other cancers that cancer cells form resistance to treatments as the disease progresses. However, these resistance mechanisms are not yet fully ...

Breakthrough research sheds light on the genetic mutation behind aggressive prostate cancer. Study: CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic ...

Research assistant Hong Wang retrieves a small, clear, plastic tray from a stainless-steel incubator and places it carefully on the laboratory bench at Monash University’s Prostate Cancer Research ...

The image shows prostate cancer cells in which KLF4 (red) and the CD44 protein (green) on the cell membrane are stained. There is a challenge related to prostate and many other cancers that cancer ...